DIPNA PHARMACHEM LIMITED

CIN: L24100GJ2011PLC066400

Regd. Office: A/211, Siddhi Vinayak Complex, Near D.A.V. School,

Makarba, Ahmedabad – 380 055 **E-mail**: dharachem99@yahoo.in

Date: 12th June, 2024

To, **BSE Limited**Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai –400 001

Dear Sir / Ma'am,

Sub: Submission of Audited Financial Results for the Half year and Year ended on 31st March, 2024 along with Auditor's Report

Ref: Security Id: DPL / Code: 543594

In reference to captioned subject and pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are hereby submitting the Audited Financial Results for the Half Year and Year ended on 31st March, 2024 along with Auditor's Report.

Please take note of the same and oblige.

For, Dipna Pharmachem Limited

KEYUR Digitally speciely SEVID (PM ONDAINA)
DIPAKKUM STATE OF SEVID (PM ONDAINA)
DIPA

Keyur Shah

Managing Director DIN: 03167258

Dipna Pharmachem Limited

CIN: L24100GJ2011PLC066400

Address: A/211, Siddhi Vinayak Complex, Near D.A.V. School, Makarba, Ahmedabad, Gujarat, India, 380055 Standalone Statement of Audited Financial Results for the Half Year & Year ended on 31st March, 2024

(Rs. in Lakhs except EPS)

		Half Year Ended Year Ended Year Ended				
				31.03.2023		
	Particulars	(Audited)	(Unaudited)	(Audited)	Ended 31st March 2024	31st March 2023
I.	Income from Operations					
	Revenue from Operations	9030.53	7403.18	5132.35	16433.71	9,992.72
	Other Income	-14.59	14.99	0.63	0.40	0.63
	Total Revenue (I)	9,015.94	7,418.17	5,132.98	16,434.11	9,993.35
II.	Expenses:					
	Cost of material consumed	0.00	0.00	0.00	0.00	0.00
	Purchases of stock in trade	9561.38	8073.95	5227.81	17635.33	10,813.00
	Changes in inventories of finished goods work-in-					
	progress and Stock-in-Trade	-911.46	-932.41	-329.00	-1843.87	-1263.9
	Employee Benefits Expenses	21.93	21.69	25.20	43.62	43.50
	Finance Costs	112.66	86.95	50.89	199.61	95.64
	Depreciation and Amortization expense	1.04	0.66	0.70	1.70	1.17
	Power & Fuel	0.06	0.48	0.08	0.54	0.30
	Other Expenses	168.18	87.06	64.40	255.24	165.56
	Total Expenses	8953.79	7338.38	5040.08	16,292.17	9,855.22
		0700117	70000	0010100	10,272117	7,000.22
III.	Profit before exceptional and extraordinary items and tax (I-II)	62.15	79.79	92.90	141.94	138.13
IV.	Exceptional Items	0.00	0.00	0.00	0.00	0.00
v.	Profit Before Extraordinary Items and Tax (III-IV)	62.15	79.79	92.90	141.94	138.1
VI.	Prior Period Items					
VII.	Profit before tax (V-VI)	62.15	79.79	92.90	141.94	138.13
VIII.	Tax expense:					
	(1) Current tax	12.85	20.75	35.00	33.6	47.0
	(2) Deferred tax	-0.19	0.00	-0.06	-0.19	-0.0
IX.	Profit (Loss) for the period from continuing					
	operations (VII-VIII)	49.49	59.04	57.96	108.53	91.19
X.	Profit/(loss) from discontinuing operations					
XI.	Tax expense of discontinuing operations					
XII.	Profit/(loss) from Discontinuing operations (after					
	tax) (X-XI)	0.00	0.00	0.00	0.00	0.0
XIII.	Profit (Loss) for the period (XI+XII)	49.49	59.04	57.96	108.53	91.19
XIV	Details of Equity Share Capital					
AIV.	Paid Up Equity Share Capital Face Value of Equity Share Capital	2404.53 10.00		1197.00 10.00	2404.53 10.00	1197.0 10.0
XV.	Reserves and Surplus	49.49	1297.85	57.96	1347.34	1238.8
XVI.	Earnings per equity share:					
	(1) Basic	0.41	0.49	0.48	0.90	0.7
	(2) Diluted	0.41	0.49	0.48	0.90	0.70

Notes:-

- 1. The above Audited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their
- respective meeting held on 12th June, 2024.

 2. The Statutory Auditors of the Company have carried out the Statutory Audit of the above financial results of the Company and have expressed an unmodified opnion on these Results.
- 3. Previous year's/period figures have been regrouped/reclassified/restated, wherever necessary to confirm to classification of current year / period. 4, AS 17 Relating to Segment wise reporting is not applicable as the Company operates in only One Primary segment i.e Pharmaceutical.

For, Dipna Pharmachem Limited

Keyur Shah **Managing Director** DIN: 03167258

Date: 12/06/2024 Place: Ahmedabad

> **KEYUR DIPAKKU** MAR SHAH

Dipna Pharmachem Limited

CIN: L24100GJ2011PLC066400

Address: A/211, Siddhi Vinayak Complex, Near D.A.V. School, Makarba, Ahmedabad, Gujarat, India, 380055

Standalone Statement of Assets & Liabilities as on March 31, 2024

		Year Ended		
	Particulars	31.03.2024 (Audited)	31.03.2023 (Audited)	
	· · · · · · · · · · · · · · · · · · ·	Rs. (In Lacs)	Rs. (In Lacs)	
I.	EQUITY AND LIABILITIES			
1	Shareholders Funds			
	(a) Share Capital	2,404.53	1,197.00	
	(b) Reserves and Surplus	1,347.34	1,238.81	
	(c) Money Received Against Share Warrents			
	Total Shareholders Funds	3,751.87	2,435.81	
3	Non-Current Liabilities	105150	1,006,03	
	(a) Long-Term Borrowings	1,254.70	1,096.93	
	(b) Deferred Tax Liabilities (Net)			
	(c) Other Long Term Liabilities			
	(d) Long-Term Provisions			
	Total Non Current Liabilites	1,254.70	1,096.93	
4	Current Liabilities			
	(a) Short-Term Borrowings	689.80	493.83	
	(b) Trade Payables			
	i) Total Outstanding dues of micro enterprise and small	4,082.58	1,690.41	
	ii) Total Outstanding dues of creditors other than micro			
	enterprise and small enterprise	3,370.98	1,937.85 13.90	
	(c) Other Current Liabilities (d) Short-Term Provisions	19.76 120.85	87.25	
	(d) Short-Term Provisions	120.00		
	Total Current Liabilities	8,283.95	4,223.23	
	TOTAL	13,290.52	7,755.97	
II.	ASSETS			
	Non-Current Assets			
1	(a) Fixed Assets	3.72	3.96	
	(i) Tangible Assets	3.72	3.70	
	(ii) Intangible Assets (iii) Capital Work-In-Progress			
	(iv) Intangible Assets under Development	-		
	(b) Non-Current Investments	_		
	(c) Deferred Tax Assets (Net)	0.25	0.06	
	(d) Long-Term Loans and Advances	-		
	(e) Other Non-Current Assets	-		
	Total Non Current Assets	3.97	4.02	
2	Current Assets			
	(a) Current Investments			
	(b) Inventories	3,738.18	1,894.31	
	(c) Trade Receivables	3,093.67	2,853.18	
	(d) Cash and Cash Equivalents	1,387.83	569.23	
	(e) Short-Term Loans and Advances	E 0.00 05	2,435.25	
	(f) Other Current Assets	5,066.87 13,286.55	.7,751.95	
	Total Current Assets	13,290.52	•7,755.97	
	TOTAL	13,290.52	7,733.97	

For, Dipna Pharmachem Limited

Keyur Shah **Managing Director** DIN: 03167258

KEYUR AR SHAH

Dipna Pharmachem Limited CIN: L24100GJ2011PLC066400

Address: A/211, Siddhi Vinayak Complex, Near D.A.V. School, Makarba, Ahmedabad, Gujarat, India, 380055

CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH 2024

Particulars	For the Year Ended 31st March, 2024	For the Very Park 1 104 134 1 1 2000
	1 of the real Ended Sist March, 2024	For the Year Ended 31st March, 2023
Cash flows from operating activities		
Profit before taxation	141.93	138.1
Adjustments for:		130.1
Depreciation	1.70	1.1
Investment income		•
Deferred tax Liability		
Interest expense	199.61	95.
Profit / (Loss) on the sale of property, plant & equipment		93.1
Working capital changes:		
(Increase) / Decrease in trade and other receivables	(240.50)	(155.7
(Increase) / Decrease in inventories	(1,843.87)	
(Increase) / Decrease in Short Term Loan & Advance	(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	(1,263.9.
(Increase) / Decrease in Other Current Assets	(2,631.62)	(2,165.1
Increase / (Decrease) in Trade payables	3,825.30	1,325.2
Increase / (Decrease) in Short term Provisions	33.60	1,525.2
Increase / (Decrease) in Other Current Liabilities	5.85	
		(73.0
Cash generated from operations		
Interest paid		
ncome taxes paid	(33.65)	
Dividends paid	(33.03)	(47.0)
Net cash from operating activities	(541.65)	(2,097.6)
Cach flows from inner the state of		(2,077.00
Cash flows from investing activities		
Purchase of property, plant and equipment	(1.46)	(1.0)
nvestment Income		(1.0.
Proceeds/(Payment) for Long Term Loans & Advances		
Increase)/Decrease in Other Non Current Assets		
ncrease in Non Current Investments		
Net cash used in investing activities	(1.46)	(1.01
Cash flows from financing activities		
Proceeds/ (Repayment) of Short term Borrowings	105.07	
Proceeds/ (Repayment) of Long term Borrowings	195.97	(266.05
Proceeds from Share Capital	157.77	837.9
Proceeds from Securities Premium	1,207.53	1,194.0
Payment of Finance cost		976.8
let cash used in financing activities	(199.61)	(95.64
=	1,361.66	2,647.0
et increase in cash and cash equivalents	818.55	548.4
ash and cash equivalents at beginning of period		370.7
	569.28	20.8
ash and cash equivalents at end of period	1,387.83	569.28

For, Dipna Pharmachem Limited

Keyur Shah Managing Director DIN: 03167258

Date: 12/06/2024 Place: Ahmedabad

KEYUR DIPAKKUM 25.4. **AR SHAH**



Independent Auditor's Report on Audited Standalone Half Yearly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

INDEPENDENT AUDITOR'S REPORT

TO THE BOARD OF DIRECTORS OF DIPNA PHARMACHEM LIMITED

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying half yearly standalone financial results of Dipna Pharmachem Limited ("the Company") for the half year ended on 31st March, 2024 and the year to date results for the period from 1st April, 2023 to 31st March, 2024 attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the half year ended on 31st March, 2024 as well as the year to date results for the period from 1st April, 2023 to 31st March, 2024.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



Management's Responsibilities for the Standalone Financial Results

These standalone half yearly financial results as well as the year to date standalone financial results have been prepared on the basis of the audited annual financial statements for the year ended on 31st March, 2024. The Company's Board of Directors is responsible for the preparation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit.



We also:

- Identify and assess the risks of material misstatement of the standalone financial
 results, whether due to fraud or error, design and perform audit procedures responsive
 to those risks, and obtain audit evidence that is sufficient and appropriate to provide a
 basis for our opinion. The risk of not detecting a material misstatement resulting from
 fraud is higher than for one resulting from error, as fraud may involve collusion,
 forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design
 audit procedures that are appropriate in the circumstances, but not for the purpose of
 expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all Relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



Other Matter:

1) The reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014 is applicable from 1 April 2023. Based on our examination which included test checks, except for the instances mentioned below, the Company has used accounting softwares for maintaining its books of account, which have a feature of recording audit trail (edit log) facility and the company has started the feature of recording Audit Trail (Edit Log) from 12th December, 2023.

For, Devadiya & Associates

AHMEDABAD R.N. 123045W M.NO. 112495

Chartered Accountants

FRN: 123045W

CA Sanjay Devadiya

Partner

Membership No. 112495

Date: 12/06/2024 Place: Ahmedabad

UDIN: 24112495BKGQMV3987

DIPNA PHARMACHEM LIMITED

CIN: L24100GJ2011PLC066400

Regd. Office: A/211, Siddhi Vinayak Complex, Near D.A.V. School,

Makarba, Ahmedabad – 380 055 **E-mail**: dharachem99@yahoo.in

Date: 12th June, 2024

To, **BSE Limited**Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai – 400 001.

Dear Sir / Madam,

Sub: Declaration in respect of Unmodified Opinion on Audited Financial Result for the Half year and Financial Year ended on 31st March, 2024

Ref: Security Id: DPL / Code: 543594

We hereby declared that the Statutory Auditor of the Company, M/s. Devadiya & Associates, Chartered Accountants, has issued Audit Report with Unmodified Opinion on Audited Financial Result for the Half Year and Financial Year ended as on 31st March, 2024.

The declaration is given in compliance to second proviso of Reg. 33(3)(d) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended by the SEBI (Listing Obligations and Disclosure Requirements) (Amendment), Regulations 2016, vide notification no. SEBI/LAD-NRO/GN/2016-17/001, dated 25th May, 2016.

Kindly take the same on your record and oblige us.

Thanking You.

For, Dipna Pharmachem Limited

KEYUR

DIPAKKUMA

R SHAH

R SHAH

R SHAH

Keyur Shah Managing Director

DIN: 03167258